

**SCHEDULING STATUS**

S4

**1 NAME OF THE MEDICINE**

**MYLAN ONDANSETRON 4 mg/2 ml (injection)**

**MYLAN ONDANSETRON 8 mg/4 ml (injection)**

**2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

**MYLAN ONDANSETRON 4 mg/2 ml:**

Each ampoule contains 4 mg ondansetron in 2 ml aqueous solution for intravenous or intramuscular administration.

*Excipients with known effect:*

MYLAN ONDANSETRON 4 mg/2 ml contains less than 1 mmol sodium (23 mg) per 2 ml ampoule that is to say essentially 'sodium free'.

Sugar free.

**MYLAN ONDANSETRON 8 mg/4 ml:**

Each ampoule contains 8 mg ondansetron in 4 ml aqueous solution for intravenous or intramuscular administration.

*Excipients with known effect:*

MYLAN ONDANSETRON 8 mg/4 ml contains less than 1 mmol sodium (23 mg) per 4 ml ampoule that is to say essentially 'sodium free'.

### 1.3.1.1 Professional Information for medicines for human use

Sugar free.

For full list of excipients, see section 6.1.

## 3 PHARMACEUTICAL FORM

### MYLAN ONDANSETRON 4 mg/2 ml:

Amber glass ampoules containing a practically odourless, colourless, clear liquid that is free of visible particles.

### MYLAN ONDANSETRON 8 mg/4 ml:

Amber glass ampoules containing a practically odourless, colourless, clear liquid that is free of visible particles.

## 4 CLINICAL PARTICULARS

### 4.1 Therapeutic indications

MYLAN ONDANSETRON is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.

MYLAN ONDANSETRON is also indicated for the prevention and treatment of post-operative nausea and vomiting. Routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and vomiting will occur.

### 4.2 Posology and method of administration

#### Posology

#### Chemotherapy and radiotherapy-induced nausea and vomiting:

The emetogenic potential of cancer therapy varies according to the doses and combinations of chemotherapy and radiotherapy regimens used.



### 1.3.1.1 Professional Information for medicines for human use

#### **Adults:**

#### **Emetogenic chemotherapy and radiotherapy:**

For most patients receiving emetogenic chemotherapy and radiotherapy, MYLAN ONDANSETRON 8 mg should be administered as a slow IV infusion (not less than 2-3 minutes) or IM injection in not less than 30 seconds immediately before treatment, followed by 8 mg of an oral formulation of ondansetron twelve hourly.

In circumstances where delayed or prolonged emesis is expected after the first 24 hours treatment with an oral formulation of ondansetron may be continued at 8 mg twice daily, for up to five days after a course of treatment.

#### **Highly emetogenic chemotherapy:**

A single dose of MYLAN ONDANSETRON 8 mg by slow IV (not less than 2-3 minutes) or IM injection in not less than 30 seconds immediately before chemotherapy has been shown to be effective in many patients.

Higher doses may be required in some patients, particularly those on high doses of cisplatin, and the doses of MYLAN ONDANSETRON should be adjusted according to the severity of the emetogenic challenge.

In these patients the following dose schedules have been shown to be effective:

A dose of 8 mg by slow IV or IM injection immediately before chemotherapy, followed by two further IV or IM doses of 8 mg two to four hours apart, or by a constant infusion of 1 mg/hour for up to 24 hours.

OR

A single dose of 16 mg diluted in 50-100 ml of 0,9 % sodium chloride or other compatible infusion fluid, infused over not less than 15 minutes immediately before chemotherapy.

A single dose greater than 16 mg should not be given due to dose-dependent increased risk of QT prolongation (see *section 4.4*).



### 1.3.1.1 Professional Information for medicines for human use

The efficacy of MYLAN ONDANSETRON in highly emetogenic chemotherapy may be enhanced by the addition of a single intravenous dose of dexamethasone phosphate 20 mg administered 30-45 minutes prior to the first MYLAN ONDANSETRON dose prior to chemotherapy.

To protect against delayed or prolonged emesis after the first 24 hours, treatment with an oral formulation of ondansetron may be continued at 8 mg twice daily, for up to 5 days after a course of treatment.

#### **Special Populations:**

##### **Children:**

Experience is currently limited, but MYLAN ONDANSETRON was effective and well tolerated in children over the age of 4 years, when given intravenously at a dose of 5 mg/m<sup>2</sup> over 15 minutes, immediately before chemotherapy, followed by oral therapy of 4 mg ondansetron every 12 hours for up to 5 days.

##### **Elderly patients:**

Based on more recent ondansetron plasma concentrations and exposure-response modelling, a greater effect on QTcF is predicted in patients ≥75 years of age compared to young adults. Specific dosing information for intravenous dosing is provided for patients over 65 years of age and over 75 years of age.

##### *Elderly patients aged 75 years or older:*

A single dose of intravenous MYLAN ONDANSETRON given for the prevention of chemotherapy-induced nausea and vomiting (CINV) must not exceed 8 mg (infused over at least 15 minutes).

##### *Adult patients aged less than 75 years:*

A single dose of intravenous MYLAN ONDANSETRON given for the prevention of CINV in adults (aged less than 75 years) must not exceed 16 mg (infused over at least 5 minutes).

##### *Elderly patients aged 65 years or older:*



### 1.3.1.1 Professional Information for medicines for human use

All intravenous doses should be diluted in 50-100 ml saline or other compatible fluid and infused over at least 15 minutes.

Repeat intravenous doses of MYLAN ONDANSETRON should be given no less than 4 hours apart.

#### **Prevention and treatment of post-operative nausea and vomiting:**

##### **Adults:**

Immediately before induction of anaesthesia, or post-operatively if the patient experiences nausea and/or vomiting occurring shortly after surgery, administer 4 mg MYLAN ONDANSETRON undiluted intramuscularly or intravenously. If given intravenously, MYLAN ONDANSETRON must be administered in not less than 30 seconds, preferably over 2-5 minutes. Alternatively, for the prevention of post-operative nausea and vomiting, 16 mg of an oral ondansetron formulation may be given one hour prior to induction of anaesthesia. Repeat dosing for patients who continue to experience nausea and/or vomiting post-operatively has not been studied. While recommended as a fixed dose for all, few people above 80 kg or below 40 kg have been studied.

##### **Special populations:**

##### **Children:**

For prevention of post-operative nausea and vomiting in paediatric patients two years and older having surgery performed under general anaesthesia, MYLAN ONDANSETRON may be administered by slow intravenous injection over 2 to 5 minutes or longer at a dose of 0,1 mg/kg up to a maximum of 4 mg either prior to, at or after induction of anaesthesia.

For the treatment of established post-operative nausea and vomiting in paediatric patients two years and older, MYLAN ONDANSETRON may be administered by slow intravenous injection at a dose of 0,1 mg/kg up to a maximum of 4 mg over not less than 2-5 minutes or preferably longer.



### 1.3.1.1 Professional Information for medicines for human use

Repeat dosing for paediatric patients who continue to experience nausea and/or vomiting has not been studied and should thus not be given.

#### **Elderly:**

Based on more recent ondansetron plasma concentrations and exposure-response modelling, a greater effect on QTcF is predicted in patients  $\geq 75$  years of age compared to young adults.

Specific dosing information for intravenous dosing is provided for patients over 65 years of age and over 75 years of age.

A slight age-related decrease in clearance, and an increase in the half-life of ondansetron is predicted, presenting as slight, clinically insignificant age-related increases in both oral bioavailability (65 %) and a prolonged elimination half-life (5 hours) of ondansetron.

#### **Patients with renal/hepatic impairment:**

There is limited information available on severely impaired renal or hepatic function.

*Patients with renal impairment:* No alteration of daily dosage or frequency of dosing, or route of administration is required.

There is limited information available on severely impaired renal function.

*Patients with hepatic impairment:* Clearance of MYLAN ONDANSETRON is significantly reduced and serum half-life significantly prolonged in patients with moderate or severe impairment of hepatic function. In such patients, a total daily dose of 8 mg should not be exceeded (*see section 4.4*).

## **4.3 Contraindications**

- MYLAN ONDANSETRON is contraindicated in patients known to have hypersensitivity to ondansetron or any of the excipients of the preparation.
- Concomitant use with apomorphine is contraindicated (*see section 4.5*).
- Concomitant use with medicines prolonging the QT interval (*see section 4.5*).



### 1.3.1.1 Professional Information for medicines for human use

- Congenital long QT syndrome.
- The use of MYLAN ONDANSETRON is contraindicated during the first 12 weeks of pregnancy, irrespective of the indication (see *section 4.6* and *section 4.4*).
- The use of MYLAN ONDANSETRON for post-operative nausea and vomiting is contraindicated in pregnancy and lactation (see *section 4.6*).

## 4.4 Special warnings and precautions for use

### Patients with hepatic impairment:

In patients with moderate or severe impairment of hepatic function, clearance of MYLAN ONDANSETRON is significantly reduced and serum half-life significantly prolonged. In such patients, a total daily dose of 8 mg should not be exceeded (see *section 4.2*).

MYLAN ONDANSETRON prolongs the QT interval in a dose-dependent manner. ECG changes including QT interval prolongation and cases of Torsade de Pointes have been reported. Caution is advised if patients have received cardiotoxic agents and in patients with a history or family history of prolonged QT syndrome (see *section 4.3* and *section 4.5*).

MYLAN ONDANSETRON should be administered with caution to patients who have or may develop prolongation of QTc. These include patients with diseases/disorders causing QT prolongation, electrolyte abnormalities, congestive heart failure, brady-dysrhythmia or patients taking other medicines that lead to QT prolongation (see *section 4.3*).

### Pregnancy:

The use of MYLAN ONDANSETRON during the first 12 weeks of pregnancy increases the risk of developing oral cleft palate and or lip to the foetus and is contraindicated during the first 12 weeks of pregnancy, irrespective of the indication (see *section 4.3* and *4.6*).



### 1.3.1.1 Professional Information for medicines for human use

#### **Serotonergic Medicines (e.g. SSRIs and SNRIs):**

There have been post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron, as in MYLAN ONDANSETRON, and other serotonergic medicines (including selective serotonin reuptake inhibitors (SSRI) and serotonin noradrenaline reuptake inhibitors (SNRIs)). If concomitant treatment with ondansetron and other serotonergic medicines is clinically warranted, appropriate observation of the patient is advised (*see section 4.5*).

Hypokalaemia and hypomagnesaemia should be corrected prior to MYLAN ONDANSETRON administration.

Patients with signs of sub-acute intestinal obstructions should be monitored following administration, as MYLAN ONDANSETRON is known to increase large bowel transit time and cause constipation.

Cross-hypersensitivity reactions have been reported in patients who previously exhibited hypersensitivity to other selective 5-HT<sub>3</sub> receptor antagonists, e.g. granisetron or dolasetron.

Respiratory events should be treated symptomatically and should be given particular attention as they may be precursors to hypersensitivity reactions.

In patients that undergo adenotonsillar surgery, prevention of nausea and vomiting with MYLAN ONDANSETRON may mask occult bleeding. Therefore, such patients should be followed carefully after MYLAN ONDANSETRON.



### 1.3.1.1 Professional Information for medicines for human use

Myocardial ischemia has been reported in patients treated with MYLAN ONDANSETRON. In some patients, especially in the case of intravenous administration, symptoms appeared immediately after administration of MYLAN ONDANSETRON. Patients should be alerted to the signs and symptoms of myocardial ischaemia.

MYLAN ONDANSETRON contains sodium, and this should be taken into consideration by patients on a sodium-restricted diet.

#### 4.5 Interaction with other medicines and other forms of Interaction

- MYLAN ONDANSETRON should not be given to patients who are taking other medicines that cause QT prolongation (*see section 4.3*) and/or cause electrolyte abnormalities (*see section 4.4*).
- Concomitant use of MYLAN ONDANSETRON with cardiotoxic medicines (e.g. anthracyclines (such as doxorubicin, daunorubicin or trastuzumab), antibiotics (e.g. erythromycin), antifungals (e.g. ketoconazole), antidysrhythmics (e.g. amiodarone) and beta blockers (e.g. atenolol or timolol) may increase the risk of dysrhythmias (*see section 4.3* and *section 4.4*).
- **Apomorphine:**  
Profound hypotension and loss of consciousness were reported when MYLAN ONDANSETRON was administered with apomorphine. Concomitant use of MYLAN ONDANSETRON with apomorphine may intensify QT prolongation (*see section 4.3* and *section 4.4*).
- **Serotonergic Medicines (e.g. SSRIs and SNRIs):**  
There have been post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular



### 1.3.1.1 Professional Information for medicines for human use

abnormalities) following the concomitant use of ondansetron and other serotonergic medicines (including SSRIs and SNRIs) (see section 4.4).

- **Tramadol:**

MYLAN ONDANSETRON may reduce the analgesic effect of tramadol.

- Ondansetron is metabolised by multiple hepatic cytochrome P450 enzymes CYP3A4, CYP2D6 and CYP1A2. Due to the multiplicity of metabolic enzymes capable of metabolising ondansetron, enzyme inhibition or reduced activity of one enzyme (e.g. CYP2D6 genetic deficiency) is usually compensated for by other enzymes.

- **Cyclophosphamide:**

MYLAN ONDANSETRON may decrease the concentration of cyclophosphamide in the blood (AUC).

- **Cisplatin:**

MYLAN ONDANSETRON may increase or decrease the concentration of cisplatin in the blood (AUC).

## 4.6 Fertility, pregnancy and lactation

### Women of childbearing potential/Contraception in males and females

Women of childbearing potential should use contraception while taking MYLAN ONDANSETRON and for 2 days after stopping treatment.

Women of childbearing potential being treated with MYLAN ONDANSETRON should not become pregnant as MYLAN ONDANSETRON is contraindicated in the first 12 weeks of pregnancy, irrespective of the cause of the nausea and vomiting (see section 4.3).

### Pregnancy

MYLAN ONDANSETRON is contraindicated for post-operative nausea and vomiting during pregnancy, as well as during the first 12 weeks of pregnancy irrespective of the indication due to the risk (see section 4.3).



### 1.3.1.1 Professional Information for medicines for human use

The first 12 weeks of pregnancy can be associated with an increased risk of developing oral cleft palate and/or lip to the foetus.

#### Breastfeeding

Ondansetron passes into the milk of lactating animals.

Mothers receiving MYLAN ONDANSETRON should therefore not breastfeed their babies.

#### Fertility

No information available.

#### 4.7 Effects on ability to drive and use machines

MYLAN ONDANSETRON causes nervous system and eye disorders which may adversely affect the ability to drive a car or operate machinery.

Caution is advised until the effects of MYLAN ONDANSETRON in patients on treatment are known (see section 4.8 Side effects).

#### 4.8 Undesirable effects

##### Tabulated list of adverse reactions

Body System	Undesirable effect		
	Frequent	Less frequent	Frequency not known
Immune system disorder:		Immediate hypersensitivity reactions sometimes severe, including anaphylaxis (e.g. anaphylaxis, bronchospasm, shortness of breath, dyspnoea, hypotension, shock, angioedema, urticarial) There may be cross-hypersensitivity with other	



1.3.1.1 Professional Information for medicines for human use

		selective 5-HT <sub>3</sub> -antagonists (see section 4.4).	
Psychiatric disorders:		Depression	
Nervous system disorders:	Headache	Seizures, movement disorders (including extrapyramidal reactions such as dystonic reactions, oculogyric crisis and dyskinesia). Dizziness during or shortly after rapid I.V administration.	
Eye disorders:		Visual disturbances (eg. blurred vision) during or shortly after rapid intravenous administration. Transient blindness predominantly during intravenous administration.	
Cardiac disorders:		Dysrhythmias Chest pain with or without ST segment depression Bradycardia ECG changes including QTc prolongation (and Torsade de Pointes)	Myocardial ischemia (see section 4.4)
Vascular disorders:	Sensation of warmth or flushing.	Hypotension Coronary vasospasm	
Respiratory, thoracic and mediastinal disorders:		Hiccups	
Gastrointestinal disorders:	Increase in large bowel transit time Constipation		
Hepato-biliary disorders:		Asymptomatic increases in aminotransferases	
Skin and subcutaneous tissue disorders:			Rashes Urticaria



### 1.3.1.1 Professional Information for medicines for human use

General disorders and administrative site conditions:	Pain, redness and burning at site of injection.		
---	---	--	--

#### **Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare providers are asked to report any suspected adverse reactions to SAHPRA via the “**6.04 Adverse Drug Reactions Reporting Form**”, found online under SAHPRA’s publications:

<https://www.sahpra.org.za/Publications/Index/8>

#### **4.9 Overdose**

In overdose, side effects can be precipitated and/or be of increased severity (*see section 4.8*).

- Manifestations that have been reported include severe constipation, visual disturbances, hypotension and a vasovagal episode with transient second-degree AV block.
- In cases of suspected overdose, symptomatic and supportive therapy should be given as appropriate, as there is no specific antidote for ondansetron.
- Ondansetron prolongs QT interval in a dose-dependent manner.
- ECG monitoring is recommended in cases of overdose.

## **5 PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

#### **PHARMACOLOGICAL CLASSIFICATION:**

A 5.10 Medicines affecting autonomic function. Serotonin antagonists.



### 1.3.1.1 Professional Information for medicines for human use

ATC group: A04AAO 1 Serotonin (5HT<sub>3</sub>) antagonist, ATC code: A04 Antiemetics and antinauseants

#### *Mechanism of Action:*

Ondansetron is a selective 5-HT<sub>3</sub> receptor-antagonist. Chemotherapeutic agents and radiotherapy may cause release of 5-HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5-HT<sub>3</sub> receptors. The initiation of this reflex is blocked by ondansetron. Activation of vagal afferents may also cause a release of 5-HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism.

Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is due to the antagonism of 5-HT<sub>3</sub> receptors on neurons located both in the peripheral and central nervous system.

#### *QT Prolongation:*

The effect of ondansetron on the QTc interval was evaluated in a double blind, randomised, placebo and positive (moxifloxacin) controlled, crossover study in 58 healthy adult men and women. Ondansetron doses included 8 mg and 32 mg infused intravenously over 15 minutes. At the highest tested dose of 32 mg, the maximum mean (upper limit of 90 % CI) difference in QTcF from placebo after baseline-correction was 19,6 (21,5) msec. At the lower tested dose of 8 mg, the maximum mean (upper limit of 90 % CI) difference in QTcF from placebo after baseline-correction was 5,8 (7,8) msec. In this study, there were no QTcF measurements greater than 480 msec and no QTcF prolongation was greater than 60 msec. No significant changes were seen in the measured electrocardiographic PR or QRS intervals.

## **5.2 Pharmacokinetic properties**

#### *Distribution:*



### 1.3.1.1 Professional Information for medicines for human use

The disposition of ondansetron following both intravenous and oral dosing is similar, with a terminal elimination half-life of about 3 hours and a steady-state volume of distribution of about 140 l. Plasma protein binding is 70-76 %.

#### *Biotransformation:*

Ondansetron is predominantly cleared from the systemic circulation by metabolism, with less than 5 % of a dose excreted unchanged in the urine.

#### *Special Patient Populations:*

##### *Elderly*

Ondansetron has a prolonged elimination half-life (5 hrs) and increased bioavailability (65 %) in the elderly.

##### *Hepatic impairment*

As a result of reduced pre-systemic metabolism in patients with severe hepatic impairment, the systemic clearance of ondansetron is markedly reduced with prolonged elimination half-lives (15-32 hrs) and a bioavailability approaching 100 %.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Citric acid, sodium chloride, sodium citrate and water for injection.

### **6.2 Incompatibilities**

MYLAN ONDANSETRON must not be mixed with other medicines except those mentioned in section 6.6.

### **6.3 Shelf life**

#### **Unopened ampoule:**



### 1.3.1.1 Professional Information for medicines for human use

36 months

#### **Opened ampoule:**

After first opening MYLAN ONDANSETRON should be used immediately.

#### **6.4 Special precautions for storage**

Store at or below 25 °C.

Protect from light.

#### **6.5 Nature and contents of container**

##### **MYLAN ONDANSETRON 4 mg/2 ml:**

1, 2, 5 or 10 amber glass ampoule/s packaged in an outer carton.

##### **MYLAN ONDANSETRON 8 mg/4 ml:**

1, 2, 5 or 10 amber glass ampoule/s packaged in an outer carton.

#### **6.6 Special precautions for disposal of a used medicine or waste materials derived from such medicine and other handling of the product**

##### **Instructions for handling injections:**

MYLAN ONDANSETRON ampoules are unpreserved and should only be used on a single occasion, and injection or diluted immediately after opening. Any remaining solutions should be discarded.

MYLAN ONDANSETRON injection ampoules should not be autoclaved.

##### **Compatibility with intravenous fluids:**

MYLAN ONDANSETRON injection should not be administered in the same syringe or infusion as any other medicine.



### 1.3.1.1 Professional Information for medicines for human use

MYLAN ONDANSETRON injection should only be admixed with those infusion solutions which are recommended.

IV admixtures should be inspected for clarity, particulate matter, precipitate discolouration and leakage prior to administration whenever solution and container permit. Solutions showing haziness, particulate matter, or discolouration or leakage should not be used.

Dilutions of MYLAN ONDANSETRON injections in intravenous fluids should be prepared at the time of infusion or stored at 2-8 °C for no more than 24 hours prior to administration.

**MYLAN ONDANSETRON should only be admixed with those infusion solutions that are recommended, namely:**

- Sodium Chloride Intravenous Infusion 0,9 % w/v.
- Glucose Intravenous Infusion 5 % w/v.
- Mannitol Intravenous Infusion 10 % w/v.
- Ringers Intravenous Infusion.
- Potassium Chloride 0,3 % m/v and Sodium Chloride 0,9 % m/v Intravenous Infusion.
- Potassium Chloride 0,3 % m/v and Glucose 5 % m/v Intravenous Infusion.
- Compatibility studies have been undertaken in polyvinyl chloride infusion bags and polyvinyl chloride administration sets. It is considered that adequate stability would also be conferred by the use of polyethylene infusion bags or Type I glass bottles.
- Dilutions of MYLAN ONDANSETRON in sodium chloride 0,9 % w/v or in glucose 5 % w/v have been demonstrated to be stable in polypropylene syringes. It is



### 1.3.1.1 Professional Information for medicines for human use

considered that MYLAN ONDANSETRON injection diluted with other compatible infusion fluids would be stable in polypropylene syringes.

- NOTE: Preparation of MYLAN ONDANSETRON infusions must be under the appropriate aseptic conditions.

#### **Compatibilities with other medicines:**

NOTE: The mixing of medicines for infusion is not generally recommended.

MYLAN ONDANSETRON injections should not be administered in the same syringe or infusion as any other medicine.

MYLAN ONDANSETRON injections may be administered by intravenous infusion at 1 mg/hour, e.g. from an infusion bag, or syringe pump.

The following medicines may be administered by the Y-site of the MYLAN ONDANSETRON giving set for ondansetron concentrations of 16 to 160 micrograms/ml (e.g. 8 mg/500 ml and 8 mg/50 ml respectively):

- **Cisplatin:** Concentrations up to 0,48 mg/ml (e.g. 240 mg in 500 ml) administered over one to eight hours.
- **Dexamethasone:** Dexamethasone sodium phosphate 20 mg may be administered as a slow intravenous injection over 2-5 minutes via the Y-site of an infusion set delivering 8 mg of MYLAN ONDANSETRON diluted in 50-100 ml of a compatible infusion fluid over approximately 15 minutes. Compatibility between dexamethasone sodium phosphate and MYLAN ONDANSETRON has been demonstrated, supporting administration of these medicines through the same giving set, with resulting in-line concentrations in the ranges of 32 µg-2,5 mg/ml for dexamethasone sodium phosphate and 8 µg -1 mg/ml for MYLAN ONDANSETRON.



### 1.3.1.1 Professional Information for medicines for human use

- **5-fluorouracil:** Concentrations up to 0,8 mg/ml (e.g. 2,4 g in 3 litres, or 400 mg in 500 ml) administered at a rate of at least 20 ml per hour (500 ml per 24 hours). Higher concentrations of 5-fluorouracil infusion may contain up to 0,045 % *m/v* magnesium chloride in addition to other excipients shown to be compatible.
- **Carboplatin:** Concentrations in the range 0,18 mg/ml to 9,9 mg/ml (e.g. 90 mg in 500 ml to 990 mg in 100 ml), administered over 10 minutes to one hour.
- **Etoposide:** Concentrations in the range 0,14 mg/ml to 0,25 mg/ml (e.g. 72 mg in 500 ml to 250 mg in 1 litre), administered over thirty minutes to one hour.
- **Ceftazidime:** Doses in the range 250 mg to 2000 mg reconstituted with water for injection, as recommended by the manufacturer (e.g. 2,5 ml for 250 mg and 10 ml for 2 g ceftazidime) and given as an intravenous bolus injection over approximately five minutes.
- **Cyclophosphamide:** Doses in the range 100 mg to 1 g, reconstituted with water for injection, 5 ml per 100 mg cyclophosphamide, as recommended by the manufacturer, and given as an intravenous bolus injection over approximately five minutes.
- **Doxorubicin:** Doses in the range 10 to 100 mg, reconstituted with water for injection, 5 ml per 10 mg doxorubicin, as recommended by the manufacturer, and given as an intravenous bolus injection over approximately five minutes.

Any unused product or waste material should be disposed of in accordance with local requirements.

## 7 HOLDER OF THE CERTIFICATE OF REGISTRATION

Viatrix Healthcare (Pty) Ltd

4 Brewery Street,



1.3.1.1 Professional Information for medicines for human use

Isando, Kempton Park,  
1600,  
Republic of South Africa

**8 REGISTRATION NUMBER(S)**

**MYLAN ONDANSETRON 4 mg/2 ml:** A39/5.10/0509

**MYLAN ONDANSETRON 8 mg/4 ml:** A39/5.10/0510

**9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

24 May 2022

**10 DATE OF REVISION OF TEXT**

13 August 2024

A handwritten signature in black ink, appearing to read 'M. K. S. S.', is written over the signature line.